Anti Clabsi
Dual-layer Antimicrobial CVC Dressing that Reduces CLABSI Risk and Removes Sutures
Company Overview
Snapshot
Founded in June 2025 by Eli Ben-Haroosh, Anti Clabsi operates with 1–10 employees. The company secured a grant from the Israel Innovation Authority in October 2025, marking a key early milestone in its development.
Business overview
Anti Clabsi is developing a next-generation central venous catheter (CVC) dressing designed to mitigate catheter-associated bloodstream infections (CLABSI) and eliminate the need for fixation sutures. Its core technology features a dual antiseptic gel that protects both the insertion site and the hub, while maintaining visibility. By replacing sutures with secure gel fixation, the company aims to reduce infection pathways, minimize needle-stick risks, and streamline clinical workflows. Anti Clabsi targets the healthcare industry, specifically providers, with a focus on improving quality metrics and economic outcomes related to hospital-acquired infections.
Log in to access full profile ›Company Intelligence Q&A
- What is Anti Clabsi's primary product?
- Anti Clabsi is developing a dual-layer antimicrobial CVC dressing engineered to reduce catheter-associated bloodstream infections (CLABSI) and eliminate the need for fixation sutures.
- When was Anti Clabsi founded?
- Anti Clabsi was founded in June 2025.
- Who is the founder of Anti Clabsi?
- Eli Ben-Haroosh is the Co-founder & CEO of Anti Clabsi.
- What is the primary sector of Anti Clabsi?
- Anti Clabsi operates in the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics.
- Has Anti Clabsi received any grants?
- In October 2025, Anti Clabsi secured a grant from the Israel Innovation Authority.